EC145: a novel targeted agent for adenocarcinoma of the lung

Bibliography

• Bonomi P, Kim K, Fairclough D, Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol 2000;18:623-31
   PubMed Web of Science ®Google Scholar
• Wozniak AJ, Crowley JJ, Balcerzak S, Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small cell lung cancer: a cooperative group study. J Clin Oncol 1992;10:1066-73
   PubMedGoogle Scholar
• Sandler A, Nemunatis J, Denham C, Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced and metastatic non-small cell lung cancer. J Clin Oncol 2000;18:122-30
   PubMed Web of Science ®Google Scholar
• Sandler A, Gray R, Perry MC. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-50
   PubMed Web of Science ®Google Scholar
• Scagliotti GV, Parikh P, von Pawel J, Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543-51
   PubMed Web of Science ®Google Scholar
• Edelman MJ, Watson D, Xiaofei W, Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy–Cancer and Leukemia Group B Trial 30203. J Clin Oncol 2008;26:848-55
   PubMed Web of Science ®Google Scholar
• Sign Y, Palombo M, Sinko PJ. Recent trends in targeted anticancer pro-drug and conjugate design. Curr Med Chem 2008;15:1802-26
   PubMed Web of Science ®Google Scholar
• Minko T, Dharap SS, Pakunlu RI. Molecular targeting of drug delivery systems to cancer. Curr Drug Targets 2004;5:389-406
   PubMed Web of Science ®Google Scholar
• Janne PA, Wang X, Socinski MA, Outcome of advanced NSCLC patients with EGFR exon 19 and 21 mutations treated with erlotinib (E) alone or in combination with carboplatin/paclitaxel (CP) in CALGB 30406. World Conference on Lung Cancer; Amsterdam; 2011
   Google Scholar
• Shaw AT, Yeap BY, Solomon BJ, Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol 2011;12:1004-12
   PubMed Web of Science ®Google Scholar
• Cannistra SA. Cancer of the ovary. N Engl J Med 2004;351:2519-29
   PubMed Web of Science ®Google Scholar
• Parker N, Turk MJ, Wertrick E, Folate receptor expression in carcinomas and normal tissues determined in a quantitative radioligand binding assay. Anal Biochem 2005;338:284-94
   PubMed Web of Science ®Google Scholar
• Weitman SD, Frazier KM, Kamen BA. The Folate receptor in central nervous system malignancies of childhood. J Neurooncol 1994;21:107-12
   PubMed Web of Science ®Google Scholar
• Toffili G, Cernigoi C, Russo A, Overexpression of folate binding protein in ovarian cancers. Int J Cancer 1997;74:193-8
   PubMed Web of Science ®Google Scholar
• Antony AC. Folate receptors. Annu Rev Nutr 1996;16:501-21
   PubMed Web of Science ®Google Scholar
• Kaen BA, Capdevila A. Receptor-mediated folate accumulation is regulated by the cellular folate content. Proc Natl Acad Sci USA 1986;83:5983-7
   PubMed Web of Science ®Google Scholar
• Keating MJ, Smith TL, McCredie KB, A four year experience with anthracycline, cytosine, arabinoside, vincristine, and prednisone combination chemotherapy in 325 adults with acute leukemia. Cancer 1981;47:2779-88
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Walters RS, Keating MJ, Results of the vincristine, doxorubicin, and dexamethasone regimen in adults with standard, and high-risk acute lymphocytic leukemia. J Clin Oncol 1990;8:994-1004
   PubMed Web of Science ®Google Scholar
• Kushner BH, Kramer K, Modak S, High-dose cychlophosphamide-irinotecan-vincristine for primary refractory neuroblastoma. Eur J Cancer 2011;47:84-9
   PubMed Web of Science ®Google Scholar
• Kalapurakal JA, Green DM, Haase G, Outcomes of children with favorable histology Wilms tumor and peritoneal implants treated in National Wilms Tumor Studies -4 and -5. Int J Radiat Oncol Biol Phys 2010;77:554-8
   PubMed Web of Science ®Google Scholar
• Harb WA, Conley BA, LoRusso P, A phase I study of the folate-targeted conjugate EC0489 in patients with refractory or advanced metastatic cancer (2010 ASCO Annual Meeting Proceedings (Post-Meeting Edition)). J Clin Oncol 2010;28(15 Suppl):3088
   Google Scholar
• Leamon CP, Parker MA, Vlahov IR. Synthesis and biological evaluation of EC20: a new folate derived 99mtc-based radiopharmaceutical. Bioconjug Chem 2002;13:1200-10
   PubMed Web of Science ®Google Scholar
• Low PS, Kularatne SA. Folate-targeted therapeutic and imaging agents for cancer. Curr Opin Chem Biol 2009;13:256-62
   PubMed Web of Science ®Google Scholar
• Leamon CP, Reddy JA. Folate targeted chemotherapy. Adv Drug Deliv Rev 2004;56(8):1127-41
   PubMed Web of Science ®Google Scholar
• Zhao XB, Li H, Lee RJ. Targeted drug delivery via folate receptors. Expert Opin Drug Deliv 2008;5:309-19
   PubMed Web of Science ®Google Scholar
• Kularatne SA, Low PS. Targeting of nanoparticles: folate receptor. Methods Mol Biol 2010;624:249-65
   PubMedGoogle Scholar
• Vlahov IR, Santhapuram HK, Kleindl PJ, Design and regioselective synthesis of a new generation of targeted chemotherapeutics. Part 1: EC145, a folic acid conjugate of desacetylvinblastine monohydrazide. Bioorg Med Chem Lett 2006;16:5093-6
   PubMed Web of Science ®Google Scholar
• Yang J, Chen K, Chen JX, Evaluation of disulfide reduction during receptor-mediated endocytosis by using FRET imaging. Proc Natl Acad Sci USA 2006;103:13872-7
   PubMed Web of Science ®Google Scholar
• Paulos CM, Reddy JA, Leamon CP, Ligand binding and kinetics of folate receptor recycling in vivo: impact on receptor medicated drug delivery. Mol Pharmacol 2004;66:1406-14
   PubMed Web of Science ®Google Scholar
• Reddy JA, Dorton R, Westrick E, Preclinical evaluation of EC145, a folate-vinca alkaloid conjugate. Cancer Res 2007;67:4434-42
   PubMed Web of Science ®Google Scholar
• Sausville W, LoRusso P, Quinn M, A phase 1 study of EC145 administered weeks 1 and 3 of a 4 week cycle in patients with refractory solid tumors (ASCO Annual Meeting Proceedings (Post-Meeting Edition)). J Clin Oncol 2007;25:2577
   Google Scholar
• Li J, Sausville EA, Klein PJ, Clinical pharmacokinetics and exposure-toxicity relationship of a folate-vinca alkaloid conjugate EC145 in cancer patients. J Clin Pharmacol 2009;49:1467-76
   PubMed Web of Science ®Google Scholar
• Leamon CP, Reddy JA, Vlahov IR, Comparative preclinical activity of the folate-targeted vinca alkaloid conjugates EC140 and EC145. Int J Cancer 2007;121:1585-92
   PubMed Web of Science ®Google Scholar
• Leamon CP, Reddy JA, Vlahov IR, Synthesis and biological evaluation of EC140: a novel folate-targeted vinca alkaloid conjugate. Bioconjug Chem 2006;17:1226-32
   PubMed Web of Science ®Google Scholar
• Reddy JA, Dorton R, Westrick E, Preclinical evaluation of EC145, a Folate-Vinca Alkaloid Conjugate. Cancer Res 2007;67:4434-42
   PubMed Web of Science ®Google Scholar
• Naumann RW, Symanowski JT, Ghamande SA, Precedent: a randomized phase II trial comparing EC145 and pegylated lisosomal doxyrubicin (PLD) versus PLD alone, in subjects with platinum-resistant ovarian cancer. Am Soc Clin Oncol Ann Meet 2010;28:5012
   Google Scholar
• Study for Women With Platinum Resistant Ovarian Cancer Evaluating EC145 in Combination With Doxil (PROCEED) Phase III Clinical trial. Endocyte. ClinicalTrials.gov. 2011.
   Google Scholar
• Reddy JA, Xu LC, Parker N, Preclinical evaluation of (99m)Tc-EC20 for imaging folate receptor-positive tumors. J Nucl Med 2004;45(5):857-66
   PubMed Web of Science ®Google Scholar
• Naumann RW, Coleman RL, Burger RA, Precedent: a randomized phase II trial comparing EC145 and pegylated liposomal doxorubicin (PLD) in combination, versus PLD alone, in subjects with platinum-resistant ovarian cancer. J Clin Oncol 2011;29(Suppl):abstract 5045
   Google Scholar
• Garon EB, Harb WA, Pal SE, EC-FV-03: a phase II study of EC145 (folate-receptor targeted therapy) in patients with advanced lung cancer. J Thorac Oncol 2009;4:452
   Google Scholar